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Acute lung affection in an endurance-trained man under
amiodarone medication
Akute Pneumonitis bei einem trainierten Individuum unter Amiodaron-
Behandlung
Abstract
Patients undergoing treatment with amiodarone can develop severe
pulmonarysideeffects.Thiseffect,whichisoftenhighlyunderestimated,
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canleadtodyspnea,pneumonitis,andfurtherfibrosis.Arecentchange
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in the labeling of amdiodarone by the American Food and Drug Admin-
Bernward Saurbier
2 istration (FDA) supports this suspicion. Tracing the symptoms back to
the causing agent can be difficult, as shown in our report. Stephan Sorichter
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Thesubjectofthiscasereportisanendurance-trained65yearoldmale
marathon runner who appeared with atrial fibrillation during a routine
check up in autumn 2003. After medical cardioversion with flecainide 1 University Clinic Freiburg,
Department of Pneumology,
Freiburg, Germany
a complaint free interval of 8 months was followed by a relapse, which
resulted in a change of medication to amiodarone. Due to misunder-
standings the patient kept on taking the amiodarone loading dose for
six weeks and returned with severe dyspnea on exertion.
2 University Clinic Freiburg,
Department of Cardiology,
Freiburg, Germany Losses in CO diffusing capacity, a lowered macrophages count and a
positivelymphocytetransformationtestweretheonlyfirsthandclinical
evidenceofamiodaroneintoxication,despitethesensationofdyspnea.
This case shows that special care has to be taken in treatment with
amiodarone. Side effects can be hard to trace and do not evidently
show a clear connection to amiodarone.
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Zusammenfassung
WirbeschreibendenFalleines65-jährigenAusdauersportlers,dersich
im Herbst 2003 mit Vorhofflimmern vorstellte. Nach medikamentöser
Kardioversion mit Flecainid folgte ein beschwerdefreies Intervall von
achtMonaten.RezidivedesVorhofflimmernserfordertendieUmstellung
aufAmiodaron.AufgrundvonMissverständnissennahmderPatientdie
Aufsättigungsdosis über einen Zeitraum von sechs Wochen ein, wobei
die ersten vier Wochen beschwerdefrei verliefen und sich über die
nächsten zwei Wochen eine ausgeprägte Atemnot entwickelte. Dieser
Fallbericht zeigt, dass die Behandlung mit Amiodaron besonderer
Sorgfaltbedarf.Nebenwirkungensindbisweilensehrschwererkennbar
und zeigen nicht immer eine klare Beziehung zu der Amiodaroneinnah-
me.
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Introduction
Amiodarone was initially developed in 1961 as a treat-
ment for angina. It was commonly used throughout
Europe as an anti-anginal medication, and was soon
foundtorestrainarrhythmias.However,firstdescriptions
of amiodarone induced pulmonary toxicity (AIPT) were
published in 1980 by Rotmensch [1]. Numerous investi-
gations took place in the 1980s in order to find the
pathomechanism of amiodarone lung damage.
AIPT is a relatively common side effect with a reported
incidence of 2 to 15 percent per year [1], [2]. It is known
that AIPT is up to nine times more likely in patients with
preexisting lung disease [3]. Our case report wants to
point out, that this also relates to well trained healthy
subjects and ought not to be underestimated.
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induced damages is like looking for a needle in a hay-
stack, since no secure clinical marker is known to proof
AIPT. Several methods have to be combined to conclude
the quest, such as bodyplethysmography, BAL, blood
parameters, and clinical signs.
Case presentation
The patient agreed to the use of his clinical data and
written informed consent was obtained for this report.
Theendurance-trained65yearoldmalemarathonrunner
(175 cm; 75 kg) appears in a very good state of physical
fitness.Beforethediagnosisofatrialfibrillationinautumn
2003 no cardiac or pulmonary diseases were known.
Since 1976 the patient repeatedly took part in various
marathonruns(15completeruns)andachievedhisbest
time in 3 hours and 15 minutes. Also he took part in nu-
meroushalf-marathonsandshort-distancecompetitions
(since1976atotalcountof29,300kmtrainingdistance).
In preparation for each marathon he embarked upon a
12 week training period, with three 15 km runs a week
andadditionalphysicalworkoutinagym.Whileexercising
foramarathonatoptheChinesewallin2002thepatient
underwentaspecialphysicalexaminationprogramatthe
University Hospital in Freiburg, Germany, Dept. for reha-
bilitation, prevention and sports medicine, showing no
evidenceofcardiacorpulmonarycomplicationsorhyper-
tension. During a routine check up in August 2003 atrial
fibrillation and perpetual arrhythmia was diagnosed by
hislocalphysician.HewassenttotheUniversityHospital
inFreiburgtoundergomedicalcardioversionwithflecain-
ide andanticoagulatory treatmentwith phenprocoumon,
followed by ASS. After primary conversion with 4 x 100
mg flecainide a stabilizing dose of 2 x 100 mg flecainide
was prescribed, but several relapses occurred for the
following 9 to 11 months due to bad compliance in
medication intake. The relapses were also treated with
flecainide. There were no signs of oedema, extrasystole
orlungcomplications,suchasdyspneaonexertion;blood
pressure rose to 150/90 mmHg, but this did not receive
any special attention.
After an interval of 11 months of treatment with flecain-
ide, anti-coagulation and recurring relapses the medica-
tion was changed to amiodarone. At this time the patient
already felt slight sensations of dyspnea due to atrial
fibrillation. On July 1, 2004 he was advised to take an
initial loading dose of 4x200 mg amiodarone for three
days; anticoagulatory treatment was kept. On July 5,
despite subjective well-being, atrial arrhythmia was still
present. The loading dose medication was set to 5x200
mgamiodaroneforthenextthreedays.OnJuly8theECG
showed a regular sinus rhythm with a first degree a-v
block. The continuing medication was set to a dose of
1x200 mg amiodarone per day. Due to a misunderstand-
ing the patient kept on taking the loading dose for the
following six weeks. Routine lung function on July 21,
2004showednoabnormalities(Figure1).However,after
that he experienced an increasing sensation of dyspnea
onexertionandloweredresilience.Thisledtoemergency
treatmentin the university hospitalin Freiburg on August
12, 2004.
Figure 1: DLCO (%), VC max (%) and FEV1 (%) in a male subject
withacuteamiodaronepneumonitisbeforeandaftercessation
of therapy (August 12, 2004). Values in % of normal value.
The patient showed a severe dyspnoe. Blood levels of
amiodarone (1.4 μg·ml
-1) and its degradation product de-
sethylamiodarone (0.9 μg·ml
-1) were nonetheless within
normal limits. In a chest radiography and chest HR-CT
with contrast medium no signs of amiodarone induced
changesinlungparenchyma,interstitialtissueorfibrosis
could be detected. No high-attenuation infiltrates could
be detected by the radiologist.
In order to evaluate a specific T-lymphocyte activation
due to amiodarone a lymphocyte proliferation test (LPT)
was performed. The result was highly positive showing a
SI of 15.1 with 100 pmol amiodarone clearly exceeding
the individual treshold value of 5.1. In contrast, lympho-
cytes from a healthy person disclosed a SI of 2.9 as the
highestvaluenotexceedingtheindividualthresholdvalue
of 3.7.
Duetothepossibilityoflungaffectionsunderamiodarone
andthepatient'sdyspnea,bronchofibroscopy,functional
lungtesting,bodyplethysmographyandcarbonmonoxide
diffusing capacity (DLCO) was measured.
Bronchofibroscopy showed marginal signs of an acute
bronchitis. A bronchial lavage (BAL) was taken from the
upperleftbronchuswhichshowedareducedpercentage
ofmacrophagecellcount(74%),neutrophilegranulocytes
(10%)andadiscreteCD
8+prominentlymphocytosis(15%)
with a CD
4+/CD
8+-Quotient of 0.17.
Bodyplethysmographyrecordsandanalysisofbloodgases
and DLCO were available from July 2004 and showed no
signs of lung disease or affection. After the high dose in-
take of amiodarone lung function analysis showed a sig-
nificant reduction in the DLCO with no relevant changes in
Vital Capacity and FEV1 (Figure 1). During standardized
six minute walking test losses in PaO2 (minimal value
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running.
A presumptive diagnosis of an amiodarone-induced pul-
monary disease was made clinically, according to the
results of the BAL with the positive LPT.
The only change made was to discontinue the use of
amiodarone. In addition nebivovol 5 mg/d was given for
five days to reduce sensations of arrhythmia. Anticoagu-
latory treatment was kept. As can be seen in Figure 1
completeremissionofDLCOtonormalvalueswasachieved
and maintained through follow-up inspections. No signs
ofotheramiodarone-inducedsideeffectscouldbedetec-
ted. In a follow up inspection in February 2005 at the
department of cardiology cardiac function proved to be
astablesinusrhythm,longtermECGandbloodpressure
controls did not show any pathological evidence. Lung
function stabilized at normal values.
Discussion
In this case, an endurance-trained individual developed
pneumonitis while receiving an accidentally high dose of
amiodarone. The most common side effects of ami-
odarone therapy are skin discoloration, photodermatitis,
hepatitis and hepatic cellular necrosis, thyroid dysfunc-
tion, corneal deposits, paresthesia, tremor, ataxy, drug
interactions, and bone marrow suppression [4], [5], [6],
none of which could be found in our patient. Etiology of
amiodarone lung toxicity is still not understood in all its
details, but it is believed that a sequence of events
damages the mitochondrial functions and ATP regenera-
tion in lung cells [7]. A favored attribute of amiodarone
is its long half life. On the contrary this leads to accumu-
lation of DEA, which is even more destructive than ami-
odarone, in peripheral tissue, contributing to its toxicity
in the lung [7]. A reduced percentage of macrophages,
an increase in neutrophiles and CD
8+ lymphocytes in BAL
fluidsincomparisontonormalareacommonfinding,but
does not allow a differentiation between amiodarone in-
ducedpneumonitisandothercomparableforms[3].Thus,
BAL can be a good method for differential diagnosis in
patients examined for AIPT [8].
LPT gauges the frequency of antigen-specific T cells, i.e.
high stimulation indices indicate a high number of cells
proliferating after the recognition of the specific antigen.
LPT is frequently used to differentiate chronic beryllium
disease and sarcoidosis [9], [10], [11] or to estimate
adverse effects of anti-tuberculosis therapy [11]. These
testsarespecificandcandifferentiatebetweendifferent
causative agents, which are also indicated by the clear
difference in SI between patient and control [11]. We did
not determine the sub-population of T cells reacting in
the amiodarone LPT, however, due to the decreased
CD
4+/CD
8+ ratio it is feasible that CD
8+ cells are important
inthepathophysiologyofamiodaroneinducedpneumon-
itis and may represent the proliferating sub-population
in LPT.
Patientswhodeveloplungdamagesoftenshowincreased
bloodlevelsofamiodaroneandevenhigherlevelsofDEA
[12]. These parameters, too, do not allow a diagnosis of
amiodarone induced lung damages, since other reports
also point out, that amiodarone-inducedside effects can
occurwithoutelevatedbloodlevelsofamiodaroneorDEA
[13]. Therefore blood concentrations prove not to be a
reliable indicator for the occurrence of side effects.
In April 2003 the Food and Drug Administration (FDA)
approvedachangeinthelabelingofamiodaroneandthe
pulmonarysideeffectsarenowclearlynoted.Retrospect-
ive studies stated that an amiodarone intake of more
than 400 mg per day leads to an estimated 10% to 17%
of lung damages in patients of which 10% turned out to
be fatal [14]. Adams et al. [15] estimate the pulmonary
side effects even at 27%. The most common changes
developing from amiodarone intoxication are dyspnea,
pneumonitis and pulmonary fibrosis. Kudenchuck et al.
[16] point out that there is only a weak correlation
betweenthedegreeofexposuretoamiodarone(indosage
and duration of treatment) and the development of lung
affections; the only predicitive risk in developing adverse
effects are initial abnormalities in pulmonary function
such as a reducedDLCO and pathologicalfindings in chest
x-ray. Additionally there is an increasing role of ami-
odarone induced ARDS in patients with pre-existing lung
damages and surgical patients [3], [14]. Ott et al. [17]
show that even low dose treatment (200 mg per day) is
a risk factor for developing lung damages ranging from
mild symptoms such as cough to ARDS. Therefore it is
notable that not even a low dose of amiodarone is
presently a safe medication, but may decrease the incid-
ence of pulmonary side effects [18]. It is noteworthy that
our patient did not show any signs of amiodarone or DEA
intoxication in his blood, despite his high dosage and
prolonged intake.
The most wide spread varying parameter is DLCO. Most
patients with amiodarone lung damages show a greater
loss in DLCO than normal patients. Adams et al. [15] show
that there was a mean loss of 20.3% in DLCO levels in pa-
tients under treatment with amiodarone than in compar-
ison with normal subjects. On the other hand it is shown
by Gleadhill et al. [1] that an isolated fall in DLCO does not
necessarily require a discontinuation of amiodarone
treatmentwhennoclinicalsignsofintoxicationaregiven.
Therefore, an unchanged DLCO value appears to be a reli-
able negative predictor of pulmonary toxicity. Pulmonary
function testing is also not proven to be statistically rele-
vant for diagnosis, since it does not allow to a distinction
from other pulmonary diseases [19]. In our case, no
changes in VC and FEV1 could be measured (Figure 1).
Despite that our patient did not show any evidence of
amiodarone induced lung changes for the first three
weeks of his high dose intake. The first notable changes
occurred in the time period July 21 to August 12, 2004
(Figure 1). The time span, in which AIPT develops varies
from acute onset up to long term affection. Dusman et
al. [12] noted AIPT from the sixth day of treatment up to
the 60th month, with the highest incidence occurring
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can occur early in treatment [6]. Even though amidarone
side effects are more likely to occur with increasing dur-
ation of treatment and cumulating dosage [13]. In pa-
tientsoftheICUfollowingthoracicsurgeryacuteAIPTand
ARDS can develop within 2 days postoperative and may
turn out fatal, especially in these patients [3], [20].
Thereisnospecifictreatmentforanamiodaroneaffected
lung. Corticosteroids might be helpful to reduce inflam-
mation,butarenotintendedforgeneralusage.Reversib-
ility of pulmonary changes, even fibrosis, by discontinu-
ation of amiodarone treatment is a well described phe-
nomenon [21], [22], [17].
Conclusions
Our case report, although a single one can act as a re-
minder of the clinical uncertainties of amiodarone use
and patientcompliance.Amiodarone is surelya safe and
very effective anti-arrhythmic drug, but should be admin-
istered with a close clinical monitoring and the lowest
dosage possible for arrhythmia control.
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